Ferrokinetics is associated with the left ventricular mass index in patients with chronic kidney disease

Acta Cardiologica

Volumn 72, Issue 4, 2017, Pages 460-466

  Tanaka, Akihito ^a   Inaguma, Daijo ^a   Watanabe, Yu ^a   Ito, Eri ^a   Kamegai, Naoki ^a   Shimogushi, Hiroya ^a   Shinjo, Hibiki ^a   Koike, Kiyomi ^a   Otsuka, Yasuhiro ^a   Takeda, Asami ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Chronic kidney disease; Ferrokinetics; Left ventricular mass index

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN STIMULATING AGENT; FERRITIN; FERROUS CITRATE FE 59; HEMOGLOBIN; HORMONE RECEPTOR STIMULATING AGENT; IRON; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR ACTIVATOR; BIOLOGICAL MARKER;

AGE; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENDER; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HEMATOLOGICAL PARAMETERS; HUMAN; IRON KINETICS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SUBSTITUTION THERAPY; SYSTOLIC BLOOD PRESSURE; TRANSFERRIN SATURATION; BLOOD; COMPLICATION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; KINETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; BIOMARKERS; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FERRITINS; HUMANS; KINETICS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSFERRIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 85028682845     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.1080/00015385.2017.1335382     Document Type: Article

References (17)

1. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-10.
2. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-75.
3. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
4. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-32.
5. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
6. Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K. An Overview of Regular Dialysis Treatment in Japan (As of 31 December. 2013). Ther Apher Dial 2015; 19: 540-74.
7. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet 2016; 388: 276-84.
8. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657-68.
9. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011; 8: 485-93.
10. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-48.
11. Ponka P. Cellular iron metabolism. Kidney Int Suppl 1999; 59: S2-11.
12. Cairo G, Bernuzzi F, Recalcati S. A precious metal: iron, an essential nutrient for all cells. Genes Nutr 2006; 1: 25-39.
13. Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci 2009; 66: 3241-61.
14. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis Suppl 2006; 47(5 Suppl 3): S16-145.
15. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006; 1 Suppl 1: S9-18.
16. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-9.
17. [No authors listed] Notice. Kidney Int Suppl 2012; 2: 279-335.